（投资中国）阿斯利康中国总经理：将持续加码在华投资

Core Insights - AstraZeneca's commitment to promoting inclusive globalization and maintaining global supply chain stability boosts confidence for multinational companies in China and global markets [1][3] - The completion of AstraZeneca's inhalation aerosol production base in Qingdao, Shandong, represents a significant investment of $750 million and is expected to produce 54 million respiratory drug units annually [1][3] Company Investment and Strategy - Since entering China in 1993, AstraZeneca has invested over $5 billion in the country, making it the company's second-largest market globally [3] - The company announced a $2.5 billion investment plan to establish its sixth global strategic R&D center in Beijing by March 2025 [3] - AstraZeneca's synchronization rate between its R&D pipeline in China and its global pipeline has reached 100%, with plans to launch 20 innovative drugs by 2030 [3] Future Outlook - AstraZeneca expresses strong confidence in the Chinese market, innovation, and manufacturing, committing to further investments and long-term development in China [3] - The company aims to contribute to the high-quality and sustainable development of China's healthcare sector, benefiting both Chinese and global patients [3]